Serum 25-hydroxyvitamin D and risk of venous thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Studyz

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 9, 2014, Pages 1455-1460

  Folsom, A R ^a   Roetker, N S ^a   Rosamond, W D ^b   Heckbert, S R ^c   Basu, S ^a   Cushman, M ^d   Lutsey, P L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b IL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Prospective studies; Pulmonary embolism; Risk factors; Venous thrombosis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; VITAMIN D;

ADULT; AFRICAN AMERICAN; ARTICLE; BODY MASS; COHORT ANALYSIS; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PROSPECTIVE STUDY; RISK FACTOR; VENOUS THROMBOEMBOLISM; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; ATHEROSCLEROSIS; BLOOD; ETHNOLOGY; INCIDENCE; LUNG EMBOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; SEASON; TREATMENT OUTCOME; UNITED STATES; VEIN THROMBOSIS;

AFRICAN AMERICANS; ATHEROSCLEROSIS; FEMALE; HUMANS; INCIDENCE; MALE; MASS SPECTROMETRY; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RISK FACTORS; SEASONS; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOSIS; VITAMIN D;

EID: 84908491682     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12665     Document Type: Article

References (21)

1. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009; 19: 73-8.
2. Lindqvist PG, Epstein E, Olsson H. Does an active sun exposure habit lower the risk of venous thrombotic events? A D-lightful hypothesis. J Thromb Haemost 2009; 7: 605-10.
3. Brøndum-Jacobsen P, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. 25-Hydroxyvitamin D concentrations and risk of venous thromboembolism in the general population with 18,791 participants. J Thromb Haemost 2013; 11: 423-31.
4. Brodin EE, Lerstad G, Grimnes G, Braekkan SK, Vik A, Brox J, Svartberg J, Jorde R, Hansen J-B. Serum levels of vitamin D are not associated with future risk of venous thromboembolism. The Tromsø Study. Thromb Haemost 2013; 109: 885-90.
5. Moscarelli L, Zanazzi M, Bertoni E, Caroti L, Rosso G, Farsetti S, Annunziata F, Paudice N, Salvadori M. Renin angiotensin system blockade and activated vitamin D as a means of preventing deep vein thrombosis in renal transplant recipients. Clin Nephrol 2011; 75: 440-50.
6. Beer TM, Venner PM, Ryan CW, Petrylak DP, Chatta G, Dean Ruether J, Chi KN, Curd JG, DeLoughery TG. High dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol 2006; 135: 392-4.
7. Wu-Wong JR. Are vitamin D receptor activators useful for the treatment of thrombosis? Curr Opin Investig Drugs 2009; 10: 919-27.
8. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009; 169: 626-32.
9. Grant WB. Higher rates of venous thromboembolism for Black-Americans are likely due to lower serum 25-hydroxyvitamin D levels. Am J Hematol 2010; 85: 907; author reply 908.
10. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, Tamez H, Zhang D, Bhan I, Karumanchi SA, Powe NR, Thadhani R. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 2013; 369: 1991-2000.
11. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117: 19-25.
12. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989; 129: 687-702.
13. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the Longitudinal Investigation of Thromboembolism Etiology. Arch Intern Med 2002; 162: 1182-9.
14. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy R, Aleksic N, Folsom AR. Coagulation factors, inflammation markers, and venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Med 2002; 113: 636-42.
15. Zakai NA, Ohira T, White R, Folsom AR, Cushman M. Activated partial thromboplastin time and risk of future venous thromboembolism. Am J Med 2008; 121: 231-8.
16. Baecke JAH, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 1982; 36: 936-42.
17. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Green T, Kusek JW, Manzi J, van Lente F, Zhang YL, Coresh J, Levey AS; for the CKD-EPI Investigators. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20-9.
18. Robinson-Cohen C, Hoofnagle AN, Ix JH, Sachs MC, Tracy RP, Siscovick DS, Kestenbaum BR, de Boer IH. Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events. JAMA2013; 310: 179-88.
19. Ocké M, Schrijver J, Obermann-de Boer GL, Bloemberg BP, Haenen GR, Kromhout D. Stability of blood (pro)vitamins during four years of storage at -20 degrees C: consequences for epidemiologic research. J Clin Epidemiol 1995; 48: 1077-85.
20. Antoniucci DM, Black DM, Sellmeyer DE. Serum 25-hydroxyvitamin D is unaffected by multiple freeze-thaw cycles. Clin Chem2005; 51: 258-61.
21. Clive DR, Sudhaker D, Giacherio D, Gupta M, Schreiber MJ, Sackrison JL, MacFarlane GD. Analytical and clinical validation of a radioimmunoassay for the measurement of 1,25 dihydroxy vitamin D. Clin Biochem 2002; 35: 517-21.